Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) identified in 2003
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …
Drug development and medicinal chemistry efforts toward SARS‐coronavirus and Covid‐19 therapeutics
The COVID‐19 pandemic caused by SARS‐CoV‐2 infection is spreading at an alarming
rate and has created an unprecedented health emergency around the globe. There is no …
rate and has created an unprecedented health emergency around the globe. There is no …
3CL protease inhibitors with an electrophilic arylketone moiety as anti-SARS-CoV-2 agents
S Konno, K Kobayashi, M Senda, Y Funai… - Journal of Medicinal …, 2021 - ACS Publications
The novel coronavirus, SARS-CoV-2, has been identified as the causative agent for the
current coronavirus disease (COVID-19) pandemic. 3CL protease (3CLpro) plays a pivotal …
current coronavirus disease (COVID-19) pandemic. 3CL protease (3CLpro) plays a pivotal …
[HTML][HTML] Artificial intelligence approach fighting COVID-19 with repurposing drugs
YY Ke, TT Peng, TK Yeh, WZ Huang, SE Chang… - Biomedical journal, 2020 - Elsevier
Background The ongoing COVID-19 pandemic has caused more than 193,825 deaths
during the past few months. A quick-to-be-identified cure for the disease will be a therapeutic …
during the past few months. A quick-to-be-identified cure for the disease will be a therapeutic …
An overview of severe acute respiratory syndrome–coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy
Severe acute respiratory syndrome (SARS) is caused by a newly emerged coronavirus that
infected more than 8000 individuals and resulted in more than 800 (10–15%) fatalities in …
infected more than 8000 individuals and resulted in more than 800 (10–15%) fatalities in …
The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020
This review fully describes the coronavirus 3CL pro peptidomimetic inhibitors and
nonpeptidic small molecule inhibitors developed from 2010 to 2020. Specifically, the …
nonpeptidic small molecule inhibitors developed from 2010 to 2020. Specifically, the …
Perspectives on SARS-CoV-2 main protease inhibitors
The main protease (Mpro) plays a crucial role in severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) replication and is highly conserved, rendering it one of the …
coronavirus 2 (SARS-CoV-2) replication and is highly conserved, rendering it one of the …
Small-molecule thioesters as SARS-CoV-2 main protease inhibitors: enzyme inhibition, structure–activity relationships, antiviral activity, and X-ray structure …
T Pillaiyar, P Flury, N Krüger, H Su… - Journal of Medicinal …, 2022 - ACS Publications
The main protease (Mpro, 3CLpro) of SARS-CoV-2 is an attractive target in coronaviruses
because of its crucial involvement in viral replication and transcription. Here, we report on …
because of its crucial involvement in viral replication and transcription. Here, we report on …
COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease
Highlights•The main protease, known as M pro, is encoded by the viral genome and is
essential for viral replication.•The effective target for drug development has been the M …
essential for viral replication.•The effective target for drug development has been the M …
Synthesis and applications of nitrogen-containing heterocycles as antiviral agents
TN Tran, M Henary - Molecules, 2022 - mdpi.com
Viruses have been a long-term source of infectious diseases that can lead to large-scale
infections and massive deaths. Especially with the recent highly contagious coronavirus …
infections and massive deaths. Especially with the recent highly contagious coronavirus …